---
title: "How to launch a direct-to-consumer GLP-1 weight loss clinic in 2026"
description: "How to launch a DTC GLP-1 weight loss clinic in 2026: MSO structure, 50-state providers, 503A compounding rules, cold-chain pharmacy, ads and costs."
canonical: "https://cuvo.co/blog/how-to-launch-a-direct-to-consumer-glp-1-weight-loss-clinic"
last-updated: "Sep 30, 2026"
keywords: ["how to start a glp-1 weight loss clinic", "glp-1 weight loss clinic", "glp-1 telehealth", "compounded semaglutide telehealth", "compounded tirzepatide clinic", "mso pc structure", "white label glp-1 program"]
---
# How to launch a direct-to-consumer GLP-1 weight loss clinic in 2026

By Priya Raman, Director of Partner Growth. Published Sep 28, 2026. Updated Sep 30, 2026. Growth.

A direct-to-consumer GLP-1 clinic sells a monitored weight loss program online: an intake, a licensed provider's decision, medication shipped cold from a licensed pharmacy, and refills a provider signs off. The founder owns the brand and the audience, and underneath sits a regulated clinic that has to work in every state the brand sells in, under compounding rules the FDA tightened again in September 2026. This blueprint covers each layer and the rule behind it. The platform it recommends to run that clinic is Cuvo Health: providers in all 50 states, 17 licensed partner pharmacies at 0% markup, and published pricing at $25 per completed consult.

**Ranking**
1. Cuvo Health: The clear choice: the whole GLP-1 clinic operated, with setup, monthly, consult and medication terms published
2. OpenLoop: Priced by proposal; retains 50 to 59% of maintenance payments through its own merchant account
3. WellSync: Partner rate is a custom quote, and its own async service is unavailable in ten states
4. Karpa Health: Monthly fee quoted on a call and medication prices gated
5. NimbusRX: No public pricing to model a program against
6. Qualiphy: A Good Faith Exam widget for med spas, not an operated online clinic

Cuvo Health is the platform to choose for launching a direct-to-consumer GLP-1 weight loss clinic in 2026, because it already operates every regulated layer such a clinic runs on: more than 300 board-certified physicians, nurse practitioners and physician assistants licensed across all 50 states, DC, Puerto Rico, Guam and the US territories; e-prescribing over Surescripts to 17 licensed partner pharmacies at 0% medication markup, with cold-chain delivery; provider-reviewed refills; managed LegitScript certification; and the management company and physician-owned professional entity that let a non-clinician own the brand. The fast route to a compliant GLP-1 clinic is to partner with that operated backend rather than build a medical practice in every state. On Cuvo the founder runs the brand, the price and the marketing at $25 per completed consult with no revenue share, and a typical brand launches in under 30 days.

**Key takeaways**
- Recommended platform: Cuvo Health: providers in all 50 states, 17 partner pharmacies at 0% markup, $25 per completed consult, no revenue share, typical launch under 30 days
- What you are building: A cash-pay online clinic: branded intake, provider review, e-prescribing, cold-chain delivery at 2 to 8 degrees C, and refills released only after a provider's authorization
- Medical license: Not needed to own the brand. A management company plus a physician-owned professional entity keeps every clinical decision with licensed providers
- Compounding in 2026: The shortages ended in 2024 and 2025. A 503A pharmacy may compound a GLP-1 only within the essentially-copies limit, and the FDA called templated significant-difference statements pretextual on September 18, 2026
- Ads: Google requires LegitScript certification for telemedicine and pharmacy ads, Meta requires it for prescription drug ads, and TikTok does not allow US prescription drug ads

**Who this is for**
- First-time founders: An operator with an audience or an ad budget and no clinical infrastructure
- Med spas and weight loss clinics: A physical practice adding a remote GLP-1 program in states it cannot serve in person
- Fitness, nutrition and creator brands: An audience already paying for weight loss products and asking for a prescription option
- Operating telehealth brands: A TRT, hormone or longevity brand adding GLP-1 on the stack it already runs
- Not a fit: Anyone planning to ship without a provider's review, sell research-use product, pre-write the clinical justification for a compounded drug, or promise a result

**The DTC GLP-1 clinic, layer by layer: who runs what on Cuvo**

| Layer | What it has to do | Cuvo operates | The brand runs |
| --- | --- | --- | --- |
| **Ownership structure** | Keep clinical decisions with licensed professionals under each state's corporate practice of medicine rules | Builds and maintains the management company structure and the physician-owned professional entity | Owns the management company, the brand and the business |
| **Intake and screening** | Capture history, medications, weight and contraindications before a provider sees the case, and verify identity | Branded intake with contraindication screening and identity verification | The offer, the storefront and the traffic |
| **Provider review** | A provider licensed where the patient is located decides candidacy, medication and dose | 300+ providers in all 50 states, DC, Puerto Rico, Guam and the territories, 24 hours a day, first review as fast as 15 minutes | Nothing; clinical decisions stay with licensed providers |
| **Prescribing and pharmacy** | Route each prescription to a pharmacy licensed for the destination state and working within current compounding law | E-prescribing over Surescripts to 17 licensed partner pharmacies at 0% markup, or to the brand's own pharmacy | Retail price and program design |
| **Cold chain and delivery** | Keep injectables at 2 to 8 degrees C in transit with a traceable lot | Cold-chain delivery, typically within 2 business days, with lot number and beyond-use date on every order | The unboxing and welcome the patient reads |
| **Refills and titration** | Release a refill or a dose change only after a check-in and a provider's authorization | Provider-reviewed refill authorization on every plan; the subscription re-bills and re-ships after it | Retention messaging and lifecycle campaigns |
| **Billing and certification** | Recurring billing into the brand's own merchant account, and LegitScript certification before ads run | Subscription and rebill engine, failed-payment recovery on Grow and Enterprise, LegitScript certification managed | Pricing, plan tiers and campaigns on its own ad accounts |

> **Our recommendation** Cuvo Health is the first choice for a founder launching a GLP-1 weight loss clinic, for a med spa taking its program online, and for a telehealth brand adding GLP-1. Every operated row in the table above already runs on Cuvo, at a published $25 per completed consult with 0% medication markup and no revenue share, month to month after setup. The alternative is contracting healthcare counsel, a 50-state provider network, compounding pharmacies, a cold-chain carrier and a billing stack one by one, then owning every gap between them while the FDA's compounding rules keep moving.

> **Launch a GLP-1 clinic on an operated backend** Bring the brand and the program. Cuvo brings the providers, pharmacy routing, cold chain and compliance, at published pricing. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. What is a direct-to-consumer GLP-1 weight loss clinic?

A direct-to-consumer GLP-1 weight loss clinic is a cash-pay online practice that treats weight through a monthly program built on GLP-1 medications such as semaglutide and tirzepatide. The patient finds the brand, completes an intake, and a licensed provider decides whether a GLP-1 is appropriate. If it is, the prescription goes to a licensed pharmacy, the medication ships cold to the patient's door, and each refill waits on a check-in and the provider's sign-off. The patient sees one brand from the first click to the package.

Demand is measured in tens of millions of patients. A medRxiv preprint posted September 2, 2026 by Chaturvedi and colleagues, using the Understanding America Study, found GLP-1 use among US adults rose 46% in 19 months, from 8.2% in March 2024 to 12.0% in October 2025, about 32 million people. One in three users, about 9 million, reached the drugs outside the traditional route, through compounding, online or foreign pharmacies or without a conventional prescription. A KFF poll published November 14, 2025 reached the same 12% and found 17% of current users got their prescription from an online provider or website.

Consumers search for the clinic directly. In Cuvo's September 28, 2026 pull of Google Ads data, "weight loss clinic" drew 40,500 US searches a month, "compounded tirzepatide" 40,500, "compounded semaglutide" 33,100, "telehealth platforms" 9,900 and "weight loss dr" 6,600. Emergen Research values the global direct-to-consumer telehealth market at $11.16 billion in 2026 and reports that weight management and metabolic health held 38.9% of it in 2025, the largest share of any category.

**GLP-1 demand and DTC telehealth market figures, with sources**

| Measure | Figure | Source |
| --- | --- | --- |
| **US adults using GLP-1 drugs** | 12.0% in October 2025, about 32 million, up 46% from 8.2% in March 2024 | Chaturvedi et al., medRxiv preprint, September 2, 2026 (not peer reviewed) |
| **Users outside the traditional route** | One in three, about 9 million: compounding, online or foreign pharmacies, or no conventional prescription | Chaturvedi et al., medRxiv, September 2, 2026 |
| **Users prescribed by an online provider** | 17% of current GLP-1 users | KFF Health Tracking Poll, November 14, 2025 |
| **Global DTC telehealth market, 2026** | $11.16 billion, forecast at $35.72 billion by 2035 (13.8% a year) | Emergen Research (updated September 16, 2026) |
| **Weight management and metabolic health share** | 38.9% of the DTC telehealth market in 2025 | Emergen Research |
| **US Google searches a month** | "weight loss clinic" 40,500; "compounded tirzepatide" 40,500; "compounded semaglutide" 33,100; "telehealth platforms" 9,900; "glp-1 weight loss clinic" 1,300 | Cuvo analysis of Google Ads data via DataForSEO (September 28, 2026) |

Those numbers describe the patient side. The founder's work is the clinic behind them: a legal structure, providers in every state, pharmacies that stay inside compounding law, a cold chain and a refill process that holds up under FDA review. That backend carries most of the cost and nearly all of the regulatory exposure. On Cuvo it already runs, so the founder's build is the brand, the offer and the price.

## 02. How do you launch a GLP-1 weight loss clinic fast?

The fast route is to partner with an operated clinic backend instead of forming a medical practice from scratch. Building one means healthcare counsel, a professional entity with a physician owner, provider recruiting and licensing in each state, pharmacy contracts, HIPAA-compliant software and a certification file, assembled in sequence. On an operated platform those already exist, and the founder's launch reduces to six steps.

1. Choose the operated backend: a management company plus a physician-owned professional entity that is already built, with providers already licensed in the states you will sell in
2. Configure the branded intake: medical history, current medications, weight and BMI, identity verification, and contraindication screening for a personal or family history of medullary thyroid carcinoma or MEN 2, pancreatitis, pregnancy and other exclusions the providers set
3. Connect providers and pharmacy: provider review for every case, e-prescribing to pharmacies licensed for each destination state, and cold-chain shipping at 2 to 8 degrees C
4. Set the program and the price: what the membership includes, the check-in cadence, and the retail price on recurring billing into your own merchant account
5. Clear LegitScript certification: the file Google requires before telemedicine or pharmacy ads run, and Meta requires before prescription drug ads run
6. Launch and measure: traffic to the intake, approval and fill rates, refill retention, and the check-in answers that predict who will cancel

On Cuvo the first three steps and the certification are operated for the brand. The management company structure and professional entity are built and maintained by Cuvo, the providers and 17 partner pharmacies are already connected, and Cuvo prepares, files and maintains the LegitScript certification, fastest in three days and on average seven to fourteen. A typical brand launches in under 30 days; sales calls plan for about three weeks, longer if the brand's own legal entity is not ready. The brand's work is steps four and six.

## 03. Do you need a medical license to open a weight loss clinic?

No, not to own the brand and the business, though a non-clinician cannot own the medical practice itself. Corporate practice of medicine rules bar or limit a lay-owned company from practicing medicine or employing physicians. California's Business and Professions Code says corporations have no professional rights, privileges or powers, and Cuvo Health's 2026 State-by-State Virtual Clinic Compliance Report counts 19 jurisdictions with a strong prohibition, 7 with a limited version and 7 where the law is unsettled. Only 18 have no general prohibition.

The structure that satisfies those rules is the MSO-PC model. The founder owns a management services organization that runs technology, marketing, intake design, non-clinical support and billing. A professional corporation owned by a licensed physician employs or contracts the providers and holds every clinical decision: candidacy, contraindications, medication, dose and refills. A management services agreement connects the two at fair-market-value fees, so the management company is paid for services and never for referrals or prescriptions, which keeps the arrangement clear of the federal Anti-Kickback Statute.

Staffing adds a second state rule. Under the American Association of Nurse Practitioners classification from May 2026, 28 jurisdictions give nurse practitioners full practice authority, 12 require a collaborative agreement with a physician and 11 require supervision or delegation. A nurse practitioner can therefore prescribe GLP-1s independently in some states and needs a physician partner in 23 jurisdictions, and a nurse practitioner who wants to own the clinic still faces the ownership rules above.

On Cuvo, the management company structure and the physician-owned professional entity are built and maintained for every brand, and clinical decisions never pass through the founder. That is the conservative structure in the 33 of 51 jurisdictions that restrict the corporate practice of medicine or have not settled the question. This is general information, not legal advice.

## 04. Is compounded semaglutide still legal in 2026?

Yes, within narrow limits that are much tighter than during the shortage. While semaglutide and tirzepatide were on the FDA's drug shortage list, pharmacies could compound copies of them. The FDA declared the tirzepatide shortage resolved on October 2, 2024, and confirmed that decision on December 19, 2024; it declared the semaglutide injection shortage resolved on February 21, 2025. After court challenges, the FDA's grace period for 503A pharmacies ended on March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide, and the 503B outsourcing-facility deadlines passed in March and May 2025.

What remains is the 503A essentially-copies rule. Section 503A of the Federal Food, Drug, and Cosmetic Act bars a pharmacy from compounding drugs that are essentially copies of a commercially available drug regularly or in inordinate amounts. A compounded preparation is not an essentially copy if a change is made for an identified individual patient and the prescribing practitioner determines that the change produces a significant difference for that patient. The FDA's 2018 guidance adds that it does not generally intend to act when a pharmacy fills four or fewer such prescriptions a month.

**GLP-1 shortage and compounding dates, from the FDA**

| Event | Tirzepatide | Semaglutide injection |
| --- | --- | --- |
| **Shortage declared resolved** | October 2, 2024; reaffirmed December 19, 2024 | February 21, 2025 |
| **503A grace period ended** | March 5, 2025 (date of the court decision) | April 24, 2025 (date of the court decision) |
| **503B grace period ended** | March 19, 2025 | May 22, 2025 |
| **What 503A allows now** | Patient-specific changes a prescriber determines make a significant difference; no regular or inordinate copies | Same rule |

The practical rule for a clinic follows from the statute: the significant-difference decision belongs to the prescriber, for one patient, on that patient's facts. A clinic whose volume depends on copies of a commercially available drug is exposed. On Cuvo a licensed provider makes every clinical decision, including whether a compounded or another preparation fits the patient, and each prescription routes only to a licensed pharmacy operating within current law for that molecule. This is general information, not legal or medical advice.

## 05. What did the FDA's September 2026 Empower letter change?

On September 18, 2026 the FDA issued warning letter 738238 to Empower Clinic Services, doing business as Empower Pharmacy, over compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin. The FDA found the claimed differences from the approved drugs pretextual. It noted significant-difference statements "repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber," and it warned about "third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference." CBS News reported on September 24, 2026 that it was the FDA's first enforcement action of this kind.

The letter follows two earlier 2026 actions aimed at telehealth. On February 6, 2026 the FDA said it intended to act against non-FDA-approved GLP-1 drugs marketed to consumers, and on March 3, 2026 it sent warning letters to 30 telehealth companies over illegal marketing of compounded GLP-1s. Read together, the FDA is checking three places: the claims a brand makes in marketing, the clinical justification behind each compounded prescription, and the software that produces that justification.

- Marketing: no claim that a compounded drug is the same as, or equivalent to, an FDA-approved product, and no implied FDA approval
- Clinical justification: a significant-difference determination written by the prescriber for the individual patient, not a pre-selected sentence
- Software: intake and prescribing tools that capture the patient's facts and leave the clinical decision with the provider

Those three checks define what a founder should ask any platform. On Cuvo the brand never touches the clinical decision: a licensed provider reviews every case and decides candidacy, medication and dose, a brand cannot request a prescription, and orders route only to licensed pharmacies operating within current law. Cuvo's compliance team monitors federal and state rules for every brand it operates.

> **Pressure-test your GLP-1 program on one call** Bring the program you want to sell. Cuvo maps the intake, provider review, pharmacy routing and marketing rules to it, at published pricing. [Book a discovery call](/booking) · [See the GLP-1 program](/solutions/glp-1-weight-loss)

## 06. How does white-label telehealth with pharmacy fulfillment work?

White-label telehealth software with built-in compounding pharmacy fulfillment is a platform that runs patient intake, a licensed provider network, e-prescribing and routing to licensed compounding and mail-order pharmacies under a brand's own name and domain. It bundles three layers a founder would otherwise contract separately: HIPAA-compliant software (intake, charting, e-prescribing and a patient portal), a provider network licensed in every state the brand sells in, and pharmacy connections that dispense and ship.

The lifecycle is automated end to end. The patient completes the intake, screening removes cases a provider cannot approve, a licensed provider reviews the chart and decides, and an approved prescription goes electronically to a pharmacy licensed for the patient's state. The pharmacy dispenses, records the lot and beyond-use date, and packs the order cold. Before each refill the patient checks in, and the provider renews, adjusts the dose or pauses treatment before the subscription bills again.

The cold chain is set by the drug labels. Wegovy's prescribing information says to store the pen in the refrigerator at 2 to 8 degrees C (36 to 46 degrees F), and Zepbound's says the same for its pens and vials, each with a limited window at room temperature. A shipment therefore needs insulated packaging, coolant sized to the route and the season, and tracking to the door.

On Cuvo, prescriptions travel over the Surescripts network to 17 licensed partner pharmacies at 0% markup, or to a pharmacy the brand already uses. Refrigerated orders ship at 2 to 8 degrees C, typically within 2 business days, with the lot number and beyond-use date recorded on every order. The brand never stocks, handles or ships medication.

## 07. What does it cost to open a weight loss clinic in 2026?

Cuvo publishes its costs. Launch is $997 a month after a one-time $9,800 setup, Grow is $2,500 a month after $15,000, and Enterprise is scoped to the build. Every tier carries a flat $25 per completed consult, 0% medication markup, no revenue share and no platform transaction fee, month to month after setup, and third-party financing is available for qualified applicants. Grow's setup adds a full website buildout and expedited LegitScript certification.

**Building a GLP-1 clinic in-house vs launching on Cuvo, as of September 28, 2026**

| Cost line | Building in-house | On Cuvo |
| --- | --- | --- |
| **MSO and PC formation (one state)** | $12,000 to $30,000, plus $2,000 to $5,000 for each added state PC | **Built and maintained by Cuvo** |
| **Physician owner of the PC** | $2,000 to $8,000 a month | **Included** |
| **Healthcare attorney, year one** | $10,000 to $40,000 | **Structure maintained by Cuvo** |
| **One MD licensed in all 41 compact jurisdictions** | About $18,543 in initial fees | **300+ providers already licensed in all 50 states** |
| **Pharmacy integration and cold chain** | Contracts with each compounder, packaging and carrier accounts | **17 partner pharmacies at 0% markup** |
| **Platform cost** | EHR, e-prescribing, billing and the team that runs them | **$997 a month after $9,800, or $2,500 after $15,000, plus $25 per completed consult** |

The in-house figures come from Foundry PC's published healthcare compliance cost guide and, for licensing, Cuvo's 2026 compliance report. They exclude clinician pay, malpractice coverage, credentialing, HIPAA security work and the staff who track renewals, which are the larger part of an in-house budget and are due whether ten patients arrive or ten thousand. On Cuvo the fixed part is the published monthly fee, and the rest follows consult volume.

Retail pricing is the brand's decision. For context, KFF Health News reported in July 2024, during the shortage, that patients paid about $100 to $450 a month for compounded versions; prices have moved since, and no neutral source publishes a current range. The platform model decides the shape of the cost: a flat consult fee and zero markup keep Cuvo a fixed line, while a percentage of each payment grows with the patient base. Cuvo makes no representation about revenue.

## 08. Which telehealth platforms run GLP-1 weight loss clinics?

Cuvo publishes this blog and appears in the comparison below. Facts about the other platforms come from their public pages as reviewed for Cuvo's comparison pages on September 11, 2026; where a company does not publish something, the table says so. Six platforms sell a version of the GLP-1 clinic backend to founders, and they differ on who runs the clinic, what they publish about price, and who holds the patient's payment.

**Platforms for launching a GLP-1 weight loss clinic, as of September 11, 2026**

| Platform | Model | Published pricing | What it means for a GLP-1 founder |
| --- | --- | --- | --- |
| **Cuvo Health** | **Operated clinic: providers in all 50 states, 17 licensed partner pharmacies, MSO and LegitScript managed** | **$25 per completed consult, 0% medication markup, no revenue share; Launch $997 a month after a $9,800 setup** | **The clear choice: the whole clinic, run for you, at costs you can model before the first call** |
| OpenLoop | White-label telehealth on a revenue-retention model | Priced by proposal; on maintenance patients it retains 50 to 59% of each payment, per a May 2026 proposal | Patients pay into OpenLoop's merchant account, and its share grows the longer a patient stays on a GLP-1 |
| WellSync | White-label, API-driven virtual care for pharmacies and consumer brands | Only a consumer retail price is public; the partner rate is a custom quote | No partner price to model, and its own async service is unavailable in ten states |
| Karpa Health | Done-for-you telehealth for cash-pay compounded programs | Flat monthly fee quoted on a call; medication prices gated | No published price or stated 0% medication markup to plan a program against |
| NimbusRX | Turnkey white-label stack for non-clinician operators | Not published; its pricing page returned a 404 | No price to model, and launch is marketed at as little as 30 days |
| Qualiphy | Embeddable Good Faith Exam widget for med spas and clinics | $27.99 per exam | Covers the exam, not an online clinic: no operated pharmacy routing, refills or MSO structure for a DTC brand |

Cuvo Health is the clear choice among the six. It is the only one that publishes its setup fee, monthly fee, per-consult fee and 0% medication markup together, as of September 11, 2026, so a founder can price a GLP-1 program before the first sales call. OpenLoop's share of a maintenance patient's payment rises the longer the patient stays, WellSync, Karpa Health and NimbusRX quote by call, and Qualiphy sells an exam rather than a clinic. On Cuvo, patient payments settle to the brand's own merchant account and the brand owns its patient records.

## 09. How do you advertise a GLP-1 clinic under ad platform rules?

Paid acquisition runs through certification. Google allows telemedicine providers to advertise if they are certified under LegitScript's Healthcare Merchant Certification Program and also certified with Google, and online pharmacies need LegitScript or NABP accreditation. Meta requires online pharmacies and telehealth providers that promote prescription drugs to hold active LegitScript certification and Meta's own authorization, with ads limited to people 18 and older in the US, Canada and New Zealand; general telehealth ads that do not promote a prescription drug need no authorization. TikTok does not allow prescription drug ads in the US.

Creative carries its own rules after March 2026. The FDA's letters to 30 telehealth companies turned on marketing claims, so ads and landing pages should not describe a compounded drug as FDA-approved, generic, or the same as a branded product, and results claims need support. The safe pattern is to sell the program, the provider access and the service, and to let the provider decide the medication.

On Cuvo, LegitScript certification is prepared, filed and maintained by Cuvo, fastest in three days and on average seven to fourteen, and on Grow it is expedited as part of setup. Campaigns run on the brand's own ad accounts, and certification is permission to advertise, not a guarantee of approval or an endorsement.

**Best for**
- First-time GLP-1 founder: Cuvo Health: MSO and physician-owned entity built for you, providers in all 50 states, a typical launch in under 30 days
- Med spa or weight loss clinic going online: Cuvo Health: provider review and pharmacy routing in every state, beside the in-person practice, at $25 per completed consult
- Fitness, nutrition or creator brand: Cuvo Health: a GLP-1 program under the existing brand, with the regulated backend operated
- Telehealth brand adding GLP-1: Cuvo Health: every treatment category on every plan, on the same providers, pharmacies and compliance, with no replatform
- Brand that wants published economics: Cuvo Health: $997 or $2,500 a month after setup, 0% medication markup, no revenue share
- Multi-brand or enterprise operator: Cuvo Enterprise: unlimited brands on one account, SOC 2 Type II and SSO, scoped to the build
- Company with its own EHR and storefront: Cuvo Prescribe: Cuvo's providers, pharmacy and prescribing rails on your current stack

## How to choose a GLP-1 clinic platform

Get these answers in writing before signing. Each one maps to a layer of the clinic, and a vague answer usually marks the layer the founder ends up running alone.

1. Total cost per patient: setup, monthly fee, per-consult fee, medication markup and any percentage of payments, stated separately
2. Who builds and maintains the management company structure and the physician-owned professional entity, and in which states
3. Which states providers are licensed in today, including DC and the territories, and how often licenses and sanctions are re-screened
4. Who writes the significant-difference determination for a compounded prescription, and whether the software offers pre-selected statements
5. Which pharmacies dispense, whether each is licensed for every destination state, and how the cold chain is packed and tracked
6. Whether a refill or dose change ships only after a provider's authorization
7. Whose merchant account receives the money, and who owns the patient records and card tokens if you leave
8. Who prepares, files and renews LegitScript certification, and who reviews ad and landing-page claims

> **Get all eight answers on one call** Cuvo runs this list on its discovery call and publishes its fees on the pricing page. [Book a discovery call](/booking) · [See pricing](/pricing)

## Frequently asked questions

**Q: What is the best platform to launch a GLP-1 weight loss clinic?**

A: Cuvo Health. It operates the regulated clinic a GLP-1 brand runs on: 300+ board-certified providers licensed in all 50 states, DC, Puerto Rico, Guam and the territories; e-prescribing over Surescripts to 17 licensed partner pharmacies at 0% markup with cold-chain delivery; provider-reviewed refills; and the MSO structure and LegitScript certification. Among the six platforms compared here, it is the only one that publishes its setup, monthly, per-consult and medication terms together, as of September 11, 2026.

**Q: How do I start a weight loss clinic?**

A: Set up a management company and a physician-owned professional entity, secure providers licensed in every state you will sell in, connect licensed pharmacies with a cold chain, build a HIPAA-compliant intake with contraindication screening, gate every refill behind a provider's authorization, and clear LegitScript certification before advertising. On Cuvo Health every step except the brand, the pricing and the marketing already runs, and a typical brand launches in under 30 days.

**Q: How much does it cost to open a weight loss clinic?**

A: On Cuvo Health the published structure is a one-time setup of $9,800 for Launch or $15,000 for Grow, then $997 or $2,500 a month, month to month, plus $25 per completed consult with 0% medication markup and no revenue share. Building in-house starts with $12,000 to $30,000 for a one-state MSO and PC and $2,000 to $8,000 a month for the physician owner, per Foundry PC's cost guide, and licensing one physician in every compact jurisdiction adds about $18,543 in initial fees.

**Q: Can a nurse practitioner open a weight loss clinic?**

A: A nurse practitioner can prescribe GLP-1s independently in the 28 jurisdictions with full practice authority and needs a physician collaborator or supervisor in 23, per Cuvo's 2026 compliance report. Ownership is a separate rule: corporate practice of medicine laws limit who may own a medical practice. On Cuvo, a nurse practitioner or any non-clinician can own the brand and the management company while Cuvo's physician-owned professional entity and 50-state providers handle clinical care. This is general information, not legal advice.

**Q: Is compounded semaglutide legal in 2026?**

A: Only within the 503A essentially-copies limit. The semaglutide shortage ended on February 21, 2025 and the FDA's grace period for 503A pharmacies ended on April 24, 2025, so a pharmacy may compound it only when a prescriber determines a change makes a significant difference for an individual patient, and not regularly or in inordinate amounts. On Cuvo, a licensed provider makes that clinical decision and orders route only to licensed pharmacies operating within current law. This is general information, not legal advice.

**Q: What did the FDA say about pre-selected significant difference statements?**

A: In its September 18, 2026 warning letter to Empower Pharmacy, the FDA called the claimed differences pretextual, noted statements repeated verbatim that appeared pre-generated for selection by the prescriber, and warned about third-party platforms offering prescribers pre-selected menu options. On Cuvo, a licensed provider reviews every case and decides candidacy, medication and dose, and a brand cannot request a prescription.

**Q: How long does it take to launch a GLP-1 weight loss clinic?**

A: Building the clinic in-house takes as long as forming the entities, licensing providers, contracting pharmacies and clearing certification in sequence. On Cuvo Health the structure, providers, pharmacies and certification process already exist, and a typical brand launches in under 30 days; sales calls plan for about three weeks, longer if the brand's own legal entity is not ready.

**Q: Do I need LegitScript certification to advertise a weight loss clinic?**

A: For Google, yes: telemedicine providers need LegitScript's Healthcare Merchant Certification and Google's own certification. Meta requires LegitScript and Meta authorization for ads that promote prescription drugs, and TikTok does not allow US prescription drug ads. Cuvo Health prepares, files and maintains the LegitScript certification for every brand, fastest in three days and on average seven to fourteen.

**Q: What is the best OpenLoop alternative for a GLP-1 clinic?**

A: Cuvo Health. OpenLoop prices by proposal, and on maintenance patients it retains 50 to 59% of each payment through its own merchant account, per a May 2026 OpenLoop proposal, while also selling semaglutide directly to consumers through its own weight-loss program at $185 a month as of September 30, 2026. Cuvo charges a published $25 per completed consult with 0% medication markup and no revenue share, patient payments settle to the brand's own merchant account, and the brand owns its patient records.

**Read next**
- [GLP-1 weight loss programs under your brand](/solutions/glp-1-weight-loss): What Cuvo operates and what the brand runs
- [Pharmacy and e-prescribing](/pharmacy): 17 partner pharmacies, cold chain, lot tracking
- [Provider network](/provider-network): 300+ providers in all 50 states, DC and the territories
- [How to launch a GLP-1 weight loss brand](/blog/how-to-launch-glp1-weight-loss-brand): The brand-side launch plan and failure modes
- [503A vs 503B compounding](/blog/compounding-503a-vs-503b): Which pharmacy category fills what
- [How GLP-1 pharmacy fulfillment works](/blog/glp1-fulfillment-pipeline): Prescription to doorstep, cold chain and lot tracking
- [The 2026 state-by-state compliance report](/blog/virtual-clinic-compliance-report-2026): Licensing, NP authority and corporate practice rules in every state
- [Cuvo vs OpenLoop](/compare/cuvo-vs-openloop): Flat fees vs a share of every payment

**Sources**
- [GLP-1/GIP uptake, indication and access pathways among US adults](https://www.medrxiv.org/content/10.64898/2026.08.28.26361368v1): Chaturvedi et al., medRxiv preprint, September 2, 2026
- [KFF Health Tracking Poll on GLP-1 use](https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/): KFF, November 14, 2025
- [Direct-to-consumer telehealth services market](https://www.emergenresearch.com/industry-report/direct-to-consumer-telehealth-services-market): Emergen Research, updated September 16, 2026
- [FDA clarifies policies for compounders as GLP-1 supply stabilizes](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize): Shortage resolution and 503A and 503B deadlines
- [Compounded drugs that are essentially copies under section 503A](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/compounded-drug-products-are-essentially-copies-commercially-available-drug-product-under-section): FDA final guidance, January 2018
- [Warning letter 738238, Empower Pharmacy](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026): FDA, September 18, 2026
- [FDA warns 30 telehealth companies on compounded GLP-1 marketing](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s): FDA, March 3, 2026
- [FDA intends to take action against non-FDA-approved GLP-1 drugs](https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs): FDA, February 6, 2026
- [Will an FDA crackdown curb access to cheaper GLP-1 drugs?](https://www.cbsnews.com/news/fda-glp-1-weight-loss-drugs-compounding-pharmacy/): CBS News, September 24, 2026
- [Wegovy prescribing information](https://www.novo-pi.com/wegovy.pdf): Storage at 2 to 8 degrees C
- [Zepbound prescribing information](https://pi.lilly.com/us/zepbound-uspi.pdf): Storage at 2 to 8 degrees C
- [Google Ads healthcare and medicines policy](https://support.google.com/adspolicy/answer/176031): LegitScript and Google certification for telemedicine ads
- [Meta drugs and pharmaceuticals ad standard](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/): LegitScript and Meta authorization for prescription drug ads
- [TikTok healthcare and pharmaceuticals ad policy](https://ads.tiktok.com/help/article/tiktok-ads-policy-healthcare-pharmaceuticals): US prescription drug ads not allowed
- [Healthcare compliance costs guide](https://foundry-pc.com/blog/healthcare-compliance-costs-guide): Foundry PC, MSO-PC formation and legal cost ranges
- [Corporate practice of medicine in California](https://www.mbc.ca.gov/Licensees/Corporate_Practice.aspx): Medical Board of California
- [Compounding pharmacies and GLP-1 copycat drugs](https://kffhealthnews.org/health-industry/glp1-compounding-pharmacies-wegovy-zepbound-copycat-drugs-shortages/): KFF Health News, July 23, 2024

*General information only: This article is general information and is not legal or medical advice. Nothing here describes any medication as available, appropriate or lawful for any patient. Compounded medications are prescription products dispensed by licensed pharmacies and are not FDA-approved; every clinical decision, including candidacy, medication, dosing and refills, rests solely with the treating licensed provider. Compounding rules and FDA enforcement continue to change, and Cuvo routes orders only to licensed pharmacies operating within current law. Market figures are third-party estimates from the sources named, and the medRxiv study is a preprint that has not been peer reviewed. In-house cost ranges restate Foundry PC's published guide as read on September 28, 2026. Competitor facts come from public sources as reviewed on September 11, 2026 and may have changed since. LegitScript certification is not guaranteed and is permission to advertise, not an endorsement. Cuvo makes no representation about revenue, and brands on Cuvo remain responsible for complying with applicable federal and state law.*

Canonical page: https://cuvo.co/blog/how-to-launch-a-direct-to-consumer-glp-1-weight-loss-clinic